Efficacy of an optimised bacteriophage cocktail to clear Clostridium difficile in a batch fermentation model

Antibiotics

Volumn 7, Issue 1, 2018, Pages 1-15

  Nale, Janet Y ^a   Redgwell, Tamsin A ^b   Millard, Andrew ^a   Clokie, Martha R J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Bacteriophages; Clostridium difficile; Clostridium difficile infection; In vitro fermentation model; Microbiome; Phage therapy

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; BATCH FERMENTATION; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; DNA EXTRACTION; DYSBIOSIS; ENTEROBACTERIACEAE; FECES ANALYSIS; FERMENTATION MODEL; HUMAN; INFECTIOUS DIARRHEA; METAGENOMICS; METHANOBACTERIACEAE; NONHUMAN; NORMAL HUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHAGE THERAPY; PRIORITY JOURNAL; RECURRENT INFECTION; WHOLE GENOME SEQUENCING;

EID: 85043227317     PISSN: None     EISSN: 20796382     Source Type: Journal    
DOI: 10.3390/antibiotics7010013     Document Type: Article

References (74)

1. De Kraker, M.E.A.; Stewardson, A.J.; Harbarth, S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016, 13, e1002184. [CrossRef] [PubMed]
2. De Kraker, M.E.A.; Davey, P.G.; Grundmann, H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: Estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011, 8, e1001104. [CrossRef] [PubMed]
3. Stewardson, A.J.; Allignol, A.; Beyersmann, J.; Graves, N.; Schumacher, M.; Meyer, R.; Tacconelli, E.; De Angelis, G.; Farina, C.; Pezzoli, F.; et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Euro Surveill. 2016, 21. [CrossRef] [PubMed]
4. Naylor, N.R.; Pouwels, K.B.; Hope, R.; Green, N.; Henderson, K.L.; Knight, G.M.; Atun, R.; Robotham, J.V.; Deeny, S. A national estimate of the health and cost burden of Escherichia coli bacteraemia in the hospital setting: The importance of antibiotic resistance. bioRxiv 2017. [CrossRef]
5. O’Neil, J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. The Review on Antimicrobial Resistance 2014. Available online: https://amr-review.org/sites/default/files/AMR% 20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of% 20nations_1.pdf (accessed on 31 December 2017).
6. Zucca, M.; Scutera, S.; Savoia, D. Novel avenues for Clostridium difficile infection drug discovery. Expert Opin. Drug Discov. 2013, 8, 459–477. [CrossRef] [PubMed]
7. Wise, R.; Blaser, M.J.; Carrs, O.; Cassell, G.; Fishman, N.; Guidos, R.; Levy, S.; Powers, J.; Norrby, R.; Tillotson, G.; et al. The urgent need for new antibacterial agents. J. Antimicrob. Chemother. 2011, 66, 1939–1940. [CrossRef] [PubMed]
8. Rai, J.; Randhawa, G.K.; Kaur, M. Recent advances in antibacterial drugs. Int. J. Appl. Med. Res. 2013, 3, 3–10.
9. Kutter, E.M.; Kuhl, S.J.; Abedon, S.T. Re-establishing a place for phage therapy in Western medicine. Future Microbiol. 2015, 10, 685–688. [CrossRef] [PubMed]
10. Abedon, S.T.; Kuhl, S.J.; Blasdel, B.G.; Kutter, E.M. Phage treatment of human infections. Bacteriophage 2011, 1, 66–85. [CrossRef] [PubMed]
11. Buttimer, C.; McAuliffe, O.; Ross, R.P.; Hill, C.; O’Mahony, J.; Coffey, A. Bacteriophages and bacterial plant diseases. Front. Microbiol. 2017, 8, 34. [CrossRef] [PubMed]
12. Cisek, A.A.; Dabrowska, I.; Gregorczyk, K.P.; Wyzewski, Z. Phage therapy in bacterial infections treatment: One hundred years after the discovery of bacteriophages. Curr. Microbiol. 2016, 74, 277–283. [CrossRef] [PubMed]
13. Regeimbal, J.M.; Jacobs, A.C.; Corey, B.W.; Henry, M.S.; Thompson, M.G.; Pavlicek, R.L.; Quinones, J.; Hannah, R.M.; Ghebremedhin, M.; Crane, N.J.; et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob. Agents Chemother. 2016, 60, 5806–5816. [CrossRef] [PubMed]
14. Sulakvelidze, A.; Alavidze, Z.; Morris, J.G.J. Bacteriophage therapy. Antimicrob. Agents Chemother. 2001, 45, 649–659. [CrossRef] [PubMed]
15. Loc-Carrillo, C.; Abedon, S.T. Pros and cons of phage therapy. Bacteriophage 2011, 1, 111–114. [CrossRef] [PubMed]
16. Wittebole, X.; De Roock, S.; Opal, S.M. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2014, 5, 226–235. [CrossRef] [PubMed]
17. Speck, P.; Smithyman, A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol. Lett. 2015, 363. [CrossRef] [PubMed]
18. Brüssow, H. What is needed for phage therapy to become a reality in Western medicine? Virology 2012, 434, 138–142. [CrossRef] [PubMed]
19. Slopek, S.; Weber-Dabrowska, B.; Dabrowski, M.; Kucharewicz-Krukowska, A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch. Immunol. Ther. Exp. 1987, 35, 569–583.
20. EBI Food Safety. FDA and USDA Extend GRAS Approval for LISTEX for All Food Products. 2007. Available online: http://www.ebifoodsafety.com/en/news-2007.aspx (accessed on 31 December 2017).
21. Kwon, J.H.; Olsen, M.A.; Dubberke, E.R. The morbidity, mortality, and costs associated with Clostridium difficile infection. Infect. Dis. Clin. N. Am. 2015, 29, 123–134. [CrossRef] [PubMed]
22. Olsen, M.A.; Young-Xu, Y.; Stwalley, D.; Kelly, C.P.; Gerding, D.N.; Saeed, M.J.; Mahé, C.; Dubberke, E.R. The burden of Clostridium difficile infection: Estimates of the incidence of cdi from U.S. Administrative databases. BMC Infect. Dis. 2016, 16. [CrossRef] [PubMed]
23. Dubberke, E.R.; Olsen, M.A. Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 2012, 55, S88–S92. [CrossRef] [PubMed]
24. Bauer, M.P.; Notermans, D.W.; van Benthem, B.H.B.; Brazier, J.S.; Wilcox, M.H.; Rupnik, M.; Monnet, D.L.; van Dissel, J.T. Clostridium difficile infection in Europe: A hospital-based survey. Lancet 2011, 377, 63–73. [CrossRef]
25. Boyle, N.M.; Magaret, A.; Stednick, Z.; Morrison, A.; Butler-Wu, S.; Zerr, D.; Rogers, K.; Podczervinski, S.; Cheng, A.; Wald, A.; et al. Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients. Antimicrob. Resist. Infect. Control 2015, 4. [CrossRef] [PubMed]
26. Lessa, F.C.; Mu, Y.; Bamberg, W.M.; Beldavs, Z.G.; Dumyati, G.K.; Dunn, J.R.; Farley, M.M.; Holzbauer, S.M.; Meek, J.I.; Phipps, E.C. et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 2015, 372, 825–834. [CrossRef] [PubMed]
27. Lessa, F.C.; Gould, C.V.; McDonald, L.C. Current status of Clostridium difficile infection epidemiology. Clin. Infect. Dis. 2012, 55, S65–S70. [CrossRef] [PubMed]
28. Kociolek, L.K.; Gerding, D.N. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 150–160. [CrossRef] [PubMed]
29. DuPont, H.L. Diagnosis and management of Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 2013, 11, 1216–1223. [CrossRef] [PubMed]
30. Shah, D.; Dang, M.D.; Hasbun, R.; Koo, H.L.; Jiang, Z.D.; DuPont, H.L.; Garey, K.W. Clostridium difficile infection: Update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev. Anti-Infect. Ther. 2010, 8, 555–564. [CrossRef] [PubMed]
31. Debast, S.B.; Bauer, M.P.; Kuijper, E.J. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 2014, 20, 1–26. [CrossRef] [PubMed]
32. Moura, I.; Spigaglia, P.; Barbanti, F.; Mastrantonio, P. Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes. J. Antimicrob. Chemother. 2013, 68, 362–365. [CrossRef] [PubMed]
33. Koss, C.A.; Baras, D.C.; Lane, S.D.; Aubry, R.; Marcus, M.; Markowitz, L.E.; Koumans, E.H. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob. Agents Chemother. 2012, 56, 4800–4805. [CrossRef] [PubMed]
34. Nelson, R.L.; Suda, K.J.; Evans, C.T. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst. Rev. 2017, 3. [CrossRef] [PubMed]
35. Poduval, R.D.; Kamath, R.P.; Corpuz, M.; Norkus, E.P.; Pitchumoni, C.S. Clostridium difficile and vancomycin-resistant enterococcus: The new nosocomial alliance. Am. J. Gastroenterol. 2000, 95, 3513–3515. [CrossRef] [PubMed]
36. Bauer, M.P.; Kuijper, E.J.; van Dissel, J.T. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 2009, 15, 1067–1079. [CrossRef] [PubMed]
37. Baines, S.D.; Wilcox, M.H. Antimicrobial resistance and reduced susceptibility in Clostridium difficile: Potential consequences for induction, treatment, and recurrence of C. difficile infection. Antibiotics 2015, 4, 267–298. [CrossRef] [PubMed]
38. Chilton, C.H.; Crowther, G.S.; Freeman, J.; Todhunter, S.L.; Nicholson, S.; Longshaw, C.M.; Wilcox, M.H. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J. Antimicrob. Chemother. 2014, 69, 451–462. [CrossRef] [PubMed]
39. Bartsch, S.M.; Umscheid, C.A.; Fishman, N.; Lee, B.Y. Is fidaxomicin worth the cost? An economic analysis. Clin. Infect. Dis. 2013, 57, 555–561. [CrossRef] [PubMed]
40. Stranges, P.M.; Hutton, D.W.; Collins, C.D. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013, 16, 297–304. [CrossRef] [PubMed]
41. Cruz, M.P. Fidaxomicin (Dificid), a novel oral macrocyclic antibacterial agent for the treatment of Clostridium difficile–associated diarrhea in adults. Pharmacol. Ther. 2012, 37, 278–281.
42. Hargreaves, K.R.; Clokie, M.R.J. Clostridium difficile phages: Still difficult? Front. Microbiol. 2014, 5. [CrossRef] [PubMed]
43. Sangster, W.; Hegarty, J.P.; Stewart, D.B. Phage therapy for Clostridium difficile infection: An alternative to antibiotics? Semin. Colon Rectal Surg. 2014, 25, 167–170. [CrossRef]
44. Meader, E.; Mayer, M.J.; Steverding, D.; Carding, S.R.; Narbad, A. Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 2013, 22, 25–30. [CrossRef] [PubMed]
45. Nale, J.Y.; Spencer, J.; Hargreaves, K.R.; Buckley, A.M.; Trzepiński, P.; Douce, G.R.; Clokie, M.R.J. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob. Agents Chemother. 2016, 60, 968–981. [CrossRef] [PubMed]
46. Nale, J.Y.; Chutia, M.; Carr, P.; Hickenbotham, P.; Clokie, M.R.J. ‘Get in early’; biofilm and wax moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages. Front. Microbiol. 2016, 7. [CrossRef] [PubMed]
47. Ramesh, V.; Fralick, J.A.; Rolfe, R.D. Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe 1999, 5, 69–78. [CrossRef]
48. Govind, R.; Fralick, J.A.; Rolfe, R.D. In vivo lysogenization of a Clostridium difficile bacteriophage φCD119. Anaerobe 2011, 17, 125–129.
49. Price, A.B.; Larson, H.E.; Crow, J. Morphology of experimental antibiotic-associated enterocolitis in the hamster: A model for human pseudomembranous colitis and antibiotic-associated diarrhoea. Gut 1979, 20, 467–475. [CrossRef] [PubMed]
50. Best, E.L.; Freeman, J.; Wilcox, M.H. Models for the study of Clostridium difficile infection. Gut Microbes 2012, 3, 145–167. [CrossRef] [PubMed]
51. Meader, E.; Mayer, M.J.; Gasson, M.J.; Steverding, D.; Carding, S.R.; Narbad, A. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 2010, 16, 549–554. [CrossRef] [PubMed]
52. Chilton, C.H.; Crowther, G.S.; Todhunter, S.L.; Nicholson, S.; Freeman, J.; Chesnel, L.; Wilcox, M.H. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J. Antimicrob. Chemother. 2014, 69, 2426–2433. [CrossRef] [PubMed]
53. Hargreaves, K.R.; Kropinski, A.M.; Clokie, M.R.J. What does the talking?: Quorum sensing signalling genes discovered in a bacteriophage genome. PLoS ONE 2014, 9, e85131. [CrossRef] [PubMed]
54. Lloyd-Price, J.; Abu-Ali, G.; Huttenhower, C. The healthy human microbiome. Genome Med. 2016, 8. [CrossRef] [PubMed]
55. Browne, H.P.; Forster, S.C.; Anonye, B.O.; Kumar, N.; Neville, B.A.; Stares, M.D.; Goulding, D.; Lawley, T.D. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 2016, 533, 543–546. [CrossRef] [PubMed]
56. Baines, S.D.; Chilton, C.H.; Crowther, G.S.; Todhunter, S.L.; Freeman, J.; Wilcox, M.H. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. J. Antimicrob. Chemother. 2013, 68, 1842–1849. [CrossRef] [PubMed]
57. Gould, I.M. The epidemiology of antibiotic resistance. Int. J. Antimicrob. Agents 2008, 32, S2–S9. [CrossRef] [PubMed]
58. Roberts, M.C.; McFarland, L.V.; Mullany, P.; Mulligan, M.E. Characterization of the genetic basis of antibiotic resistance in Clostridium difficile. J. Antimicrob. Chemother. 1994, 33, 419–429. [CrossRef] [PubMed]
59. Abhilash, M.; Vidya, A.G.; Jagadevi, T. Bacteriophage therapy: A war against antibiotic resistant bacteria. Internet J. Altern. Med. 2009, 7, 1.
60. Bauer, M.P.; van Dissel, J.T. Alternative strategies for Clostridium difficile infection. Int. J. Antimicrob. Agents 2009, 33, S51–S56. [CrossRef]
61. Wall, S.K.; Zhang, J.; Rostagno, M.H.; Ebner, P.D. Phage therapy to reduce preprocessing salmonella infections in market-weight swine. Appl. Environ. Microbiol. 2010, 76, 48–53. [CrossRef] [PubMed]
62. Macfarlane, G.T.; Macfarlane, S.; Gibson, G.R. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb. Ecol. 1998, 35, 180–187. [CrossRef] [PubMed]
63. Taslim, H. Clostridium difficile infection in the elderly. Acta Medica Indonesiana 2009, 41, 148–151. [PubMed]
64. McGowan, K.L.; Kader, H.A. Clostridium difficile infection in children. Clin. Microbiol. Newsl. 1999, 21, 49–53. [CrossRef]
65. Lagier, J.C.; Million, M.; Hugon, P.; Armougom, F.; Raoult, D. Human gut microbiota: Repertoire and variations. Front. Cell. Infect. Microbiol. 2012, 2. [CrossRef] [PubMed]
66. Antharam, V.C.; Li, E.C.; Ishmael, A.; Sharma, A.; Mai, V.; Rand, K.H. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J. Clin. Microbiol. 2013, 51, 2884–2892. [CrossRef] [PubMed]
67. Miyajima, F.; Roberts, P.; Swale, A.; Price, V.; Jones, M.; Horan, M.; Beeching, N.; Brazier, J.; Parry, C.; Pendleton, N.; et al. Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom. PLoS ONE 2011, 6, e22804. [CrossRef] [PubMed]
68. Chan, B.K.; Abedon, S.T.; Loc-Carrillo, C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013, 8, 769–783. [CrossRef] [PubMed]
69. Britton, R.A.; Young, V.B. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 2012, 20, 313–319. [CrossRef] [PubMed]
70. Zuo, T.; Wong, S.H.; Lam, K.; Lui, R.; Cheung, K.; Tang, W.; Ching, J.Y.L.; Chan, P.K.S.; Chan, M.C.W.; Wu, J.C.Y. et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 2017. [CrossRef] [PubMed]
71. Ott, S.J.; Waetzig, G.H.; Rehman, A.; Moltzau-Anderson, J.; Bharti, R.; Grasis, J.A.; Cassidy, L.; Tholey, A.; Fickenscher, H.; Seegert, D.; et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology 2017, 152, 799–811. [CrossRef] [PubMed]
72. Wood, D.E.; Salzberg, S.L. Kraken: Ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 2014, 15. [CrossRef] [PubMed]
73. Breitwieser, F.P.; Salzberg, S.L. Pavian: Interactive analysis of metagenomics data for microbiomics and pathogen identification. bioRxiv 2016. [CrossRef]
74. Heng, L. Aligning Sequence Reads, Clone Sequences and Assembly Contigs with Bwa-Mem. Available online: https://arxiv.org/abs/1303.3997 (accessed on 31 December 2017).